Related Experiment Video
Updated: Feb 23, 2026
06:16
Subconjunctival Administration of Adeno-associated Virus Vectors in Small Animal Models
Published on: March 16, 2022
3.7K
Summary
The FDA approved inotuzumab ozogamicin for acute lymphoblastic leukemia. This approval may lead to new uses and stimulate research into antibody-drug conjugates.
Area of Science:
- Oncology
- Pharmacology
Background:
- Acute lymphoblastic leukemia (ALL) presents challenges in relapsed or refractory cases.
- Targeted therapies are crucial for improving outcomes in hematologic malignancies.
Purpose of the Study:
- To report the FDA approval of inotuzumab ozogamicin for specific ALL patient populations.
- To highlight the potential implications of this approval for future research and therapeutic strategies.
Main Methods:
- Review of FDA regulatory decision and supporting clinical data.
- Analysis of the drug's mechanism of action as an antibody-drug conjugate.
Main Results:
- Inotuzumab ozogamicin received FDA approval for relapsed or refractory ALL.
- The drug is under investigation as a first-line treatment in combination regimens.
Conclusions:
- The approval signifies a potential advancement in ALL treatment.
- This decision may foster further investigation into antibody-drug conjugates for various cancers.
Related Concept Videos
01:26FDA Approved Drugs: Changes to Approved Drugs
290
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
290
01:11Clinical Trials: Overview
5.1K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.1K
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
30
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
30
01:25Drug Regulation
3.2K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
3.2K
01:28Preclinical Development: Overview
6.1K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.1K
01:26Drug Administration and Therapy Phases: Overview
1.5K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.5K